Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice

Vaccine

Volumn 25, Issue 52, 2007, Pages 8771-8781

  Mazumder, Saumyabrata ^a   Ravindran, Rajesh ^a   Banerjee, Antara ^a   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Cationic liposomes; ISS bearing non coding pDNA; Leishmania donovani; Soluble leishmanial antigen

Indexed keywords

ANTIGEN; LEISHMANIAL ANTIGEN; LIPOSOME; PLASMID DNA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; IMMUNE RESPONSE; IMMUNOPHARMACOLOGY; IMMUNOSTIMULATION; INNATE IMMUNITY; LEISHMANIA DONOVANI; LIPOSOMAL GENE DELIVERY SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; VISCERAL LEISHMANIASIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, PROTOZOAN; CYTOKINES; DNA, BACTERIAL; FEMALE; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIPOSOMES; LIVER; LYMPHOCYTES; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES; SPLEEN; TH1 CELLS;

EID: 36549050775     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.10.028     Document Type: Article

References (62)

1. Seaman J., Mercer A.J., and Sondorp E. The epidemic of visceral leishmaniasis in Western Upper Nile, Southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol 25 4 (1996) 862-871
2. Melby P.C., Ogden G.B., Flores H.A., Zhao W., Geldmacher C., Biediger N.M., et al. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect Immun 68 10 (2000) 5595-5602
3. Olivier M., Badaro R., Medrano F.J., and Moreno J. The pathogenesis of Leishmania/HIV co-infection: cellular and immunological mechanisms. Ann Trop Med Parasitol Suppl. 1 (2003) 79-98
4. Russo R., Laguna F., Lopez-velez R., Medrano F.J., Rosenthal E., Cacopardo B., et al. Visceral leishmaniasis with those infected with HIV: clinical aspects and other opportunistic infections. Ann Trop Med Parasitol 97 Suppl. 1 (2003) 99-105
5. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6 11 (2001) 849-854
6. Ravindran R., and Ali N. Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis. Curr Mol Med 4 6 (2004) 711-723
7. Kedzierski L., Zhu Y., and Handman E. Leishmania vaccines: progress and problems. Parasitology 133 Suppl. (2006) S87-S112
8. Khamesipour A., Rafati S., Davoudi F., Maboudi F., and Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res 123 3 (2006) 423-438
9. Uzonna J.E., Wei G., Yurkowski D., and Bretscher P. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J Immunol 167 12 (2001) 6967-6974
10. Belkaid Y., Piccirillo C.A., Mendez S., Shevach E.M., and Sacks D.L. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420 6915 (2002) 502-507
11. Gurunathan S., Wu C.Y., Freidag B.L., and Seder R.A. DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol 12 4 (2000) 442-447
12. Lowe D.B., Shearer M.H., and Kennedy R.C. DNA vaccines: successes and limitations in cancer and infectious disease. J Cell Biochem 98 2 (2006) 235-242
13. Sharifi I., Fekri A., Aflatonian M., Khamesipour A., Nadim A., Mousavi M.R., et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351 9115 (1998) 1540-1543
14. Armijos R.X., Weigel M.M., Aviles H., Maldonado R., and Racines J. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J Infect Dis 177 5 (1998) 1352-1357
15. Momeni A.Z., Jalayer T., Emamjomeh M., Khamesipour A., Zicker F., Ghassemi R.L., et al. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17 5 (1999) 466-472
16. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 6522 (1995) 546-549
17. Sato Y., Roman M., Tighe H., Lee D., Corr M., Nguyen M.D., et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273 5273 (1996) 352-354
18. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4 4 (2004) 249-258
19. Klinman D.M. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol 25 3-4 (2006) 135-154
20. Sparwasser T., Miethke T., Lipford G., Erdmann A., Hacker H., Heeg K., et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor alpha-mediated shock. Eur J Immunol 27 7 (1997) 1671-1679
21. Hartmann G., Weiner G.J., and Krieg A.M. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 96 16 (1999) 9305-9310
22. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., and Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 93 7 (1996) 2879-2883
23. Cowdery J.S., Chace J.H., Yi A.K., and Krieg A.M. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol 156 12 (1996) 4570-4575
24. Yamamoto S., Yamamoto T., Kataoka T., Kuramoto E., Yano O., and Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J Immunol 148 12 (1992) 4072-4076
25. Ballas Z.K., Rasmussen W.L., and Krieg A.M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157 5 (1996) 1840-1845
26. Rhee E.G., Mendez S., Shah J.A., Wu C.Y., Kirman J.R., Turon T.N., et al. Vacccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J Exp Med 195 12 (2002) 1565-1573
27. Miconnet I., Koenig S., Speiser D., Krieg A., Guillaume P., Cerottini J.C., et al. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 168 3 (2002) 1212-1218
28. Iborra S., Carrion J., Anderson C., Alonso C., Sacks D., and Soto M. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice. Infect Immun 73 9 (2005) 5842-5852
29. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M.D., Sato Y., Ronaghy A., et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 3 8 (1997) 849-854
30. Zelenay S., Elias F., and Flo J. Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotides. Eur J Immunol 33 5 (2003) 1382-1392
31. Stacey K.J., Sweet M.J., and Hume D.A. Macrophages ingest and are activated by bacterial DNA. J Immunol 157 5 (1996) 2116-2122
32. Gregoriadis G., Bacon A., Caparros-Wanderley W., and McCormack B. A role for liposomes in genetic vaccination. Vaccine 20 Suppl. 5 (2002) B1-B9
33. Felnerova D., Viret J.F., Gluck R., and Moser C. Liposomes virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 15 6 (2004) 518-529
34. Locher C.P., Witt S.A., Ashlock B.M., and Levy J.A. Evaluation of genetic immunization adjuvants to improve the effectiveness of a human immunodeficiency virus type 2 (HIV-2) envelope DNA vaccine. DNA Cell Biol 23 2 (2004) 107-110
35. Lowrie D.B., Tascon R.E., Bonato V.L., Lima V.M., Faccioli L.H., Stavropoulos E., et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 400 6741 (1999) 269-271
36. Bhowmick S., Ravindran R., and Ali N. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. Vaccine 25 35 (2007) 6544-6556
37. Afrin F., and Ali N. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect Immun 65 6 (1997) 2371-2377
38. Afrin F., Rajesh R., Anam K., Gopinath M., Pal S., and Ali N. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infect Immun 70 12 (2002) 6697-6706
39. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 1 (1951) 265-275
40. Gursel M., Tunca S., Ozkan M., Ozcengiz G., and Alaeddinoglu G. Immunoadjuvant action of plasmid DNA in liposomes. Vaccine 17 11-12 (1999) 1376-1383
41. Stauber L.A., Franchino E.M., and Grun J. An eight day method for screening compounds against Leishmania donovani in the golden hamster. J Protozool 5 4 (1958) 269-273
42. Titus R.G., Marchand M., Boon T., and Louis J.A. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 7 5 (1985) 545-555
43. Krieg A.M., Yi A.K., Schorr J., and Davis H.L. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol 6 1 (1998) 23-27
44. Son K.K., Patel D.H., Tkach D., and Park A. Cationic liposome and plasmid DNA complexes formed in serum-free medium under optimum transfection condition are negatively charged. Biochim Biophys Acta 1466 1-2 (2000) 11-15
45. Sellins K., Fradkin L., Liggitt D., and Dow S. Type I interferons potently suppress gene expression following gene delivery using liposome-DNA complexes. Mol Ther 12 3 (2005) 451-459
46. Gregoriadis G., Saffie R., and de Souza J.B. Liposome-mediated DNA vaccination. FEBS Lett 402 2-3 (1997) 107-110
47. Requena J.M., Iborra S., Carrion J., Alonso C., and Soto M. Recent advances in vaccines for leishmaniasis. Expert Opin Biol Ther 4 9 (2004) 1505-1517
48. Ahmed S., Colmenares M., Soong L., Goldsmith-Pestana K., Munstermann L., Molina R., et al. Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis. Infect Immun 71 1 (2003) 401-410
49. Khabiri A.R., Bagheri F., and Assmar M. Leishmania major: species specific delayed hypersensitivity reaction induced by exogenous secreted antigen in the guinea pig. Exp Parasitol 112 3 (2006) 184-186
50. Dannenberg Jr. A.M. Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis. Immunol Today 12 7 (1991) 228-233
51. Titus R.G., Lima G.C., Engers H.D., and Louis J.A. Exacerbation of murine cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T cell populations capable of mediating Leishmania major-specific delayed-type hypersensitivity. J Immunol 133 3 (1984) 1594-1600
52. Connell N.D., Medina-Acosta E., McMaster W.R., Bloom B.R., and Russell D.G. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proc Natl Acad Sci USA 90 24 (1993) 11473-11477
53. Sher A., and Coffman R.L. Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu Rev Immunol 10 (1992) 385-409
54. Murray H.W., Montelibano C., Peterson R., and Sypek J.P. Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. J Infect Dis 182 5 (2000) 1497-1502
55. Squires K.E., Schreiber R.D., McElrath M.J., Rubin B.Y., Anderson S.L., and Murray H.W. Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J Immunol 143 12 (1989) 4244-4249
56. Melby P.C., Yang J., Zhao W., Perez L.E., and Cheng J. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 69 8 (2001) 4719-4725
57. Stager S., Smith D.F., and Kaye P.M. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 165 12 (2000) 7064-7071
58. Mazumdar T., Anam K., and Ali N. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 22 9-10 (2004) 1162-1171
59. Hattori Y., Kawakami S., Lu Y., Nakamura K., Yamashita F., and Hashida M. Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration. J Gene Med 8 7 (2006) 824-834
60. Gursel I., Gursel M., Ishii K.J., and Klinman D.M. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 167 6 (2001) 3324-3328
61. Rocha A., Ruiz S., and Coll J.M. Improvement of DNA transfection with cationic liposomes. J Physiol Biochem 58 1 (2002) 45-56
62. Babiuk S., Mookherjee N., Pontarollo R., Griebel P., van Drunen Littel-van den Hurk S., Hecker R., et al. TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine. Immunology 113 1 (2004) 114-120